Molecular Partners Ag (MOLN) Free Cash Flow (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Free Cash Flow of -$18188.4 for Q1 2026, up 1.68% year-over-year from -$17888.1 in Q1 2025, and up 99.97% quarter-over-quarter from -$65.0 million in Q4 2025.
Molecular Partners Ag (MOLN) Free Cash Flow (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Free Cash Flow for 7 consecutive years, with -$18188.4 the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 1.68% year-over-year to -$18188.4; the TTM figure through Mar 2026 stood at -$63.8 million (up 4.63% YoY), while the FY2025 annual figure was -$65.0 million, up 4.99% from the prior year.
- Free Cash Flow improved to -$18188.4 in Q1 2026 per MOLN's latest filing, from -$65.0 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $157.0 million in Q2 2022 and bottomed at -$156.6 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$4.4 million across 5 years, with a median of -$18499.0 in 2025.
- On a YoY basis, Free Cash Flow climbed as much as 633.09% in 2022 and fell as far as 375.79% in 2022.
- Molecular Partners Ag's Free Cash Flow stood at $121.7 million in 2022, then tumbled by 155.15% to -$67.1 million in 2023, then slipped by 1.89% to -$68.4 million in 2024, then climbed by 4.99% to -$65.0 million in 2025, then soared by 99.97% to -$18188.4 in 2026.
- Business Quant data shows MOLN's Free Cash Flow at -$18188.4 in Q1 2026, -$65.0 million in Q4 2025, and $37.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -18,188.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,188.38 |
| Mar 31, 2026 | -18,188.38 |
| Dec 31, 2025 | -64.98 Mn |
| Dec 31, 2025 | -64.98 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Jun 30, 2025 | -35.78 Mn |
| Jun 30, 2025 | -35.78 Mn |
| Mar 31, 2025 | -18,498.95 |
| Mar 31, 2025 | -18,498.95 |
| Dec 31, 2024 | -68.39 Mn |
| Dec 31, 2024 | -68.39 Mn |
| Sep 30, 2024 | 37.41 Mn |
| Sep 30, 2024 | 37.41 Mn |
| Jun 30, 2024 | -35.87 Mn |
| Jun 30, 2024 | -35.87 Mn |
| Mar 31, 2024 | -19,392.96 |
| Mar 31, 2024 | -19,392.96 |
| Dec 31, 2023 | -67.12 Mn |
| Dec 31, 2023 | -67.12 Mn |